CD33-targeted antibody- radioimmunoconjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Actimab-A (lintuzumab-Ac225) / Actinium
NCT01756677: Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients

Checkmark Efficacy and safety data from P1 portion of P1/2 trial in AML
Jun 2016 - Jun 2016: Efficacy and safety data from P1 portion of P1/2 trial in AML
Checkmark asco-2015
May 2015 - May 2015: asco-2015
Active, not recruiting
1/2
24
US
Cytarabine, Cytosar, Ara-C, DepoCyt, Cytosine arabinosine hydrochloride, Low dose Ara-C, LDAC, Lintuzumab-Ac225, Lintuzumab, Lasix, furosemide, Spironolactone
M.D. Anderson Cancer Center, Actinium Pharmaceuticals
Leukemia
10/16
 
NCT03867682: Venetoclax and Lintuzumab-Ac225 in AML Patients

Hourglass Jan 2021 - Dec 2021 : Completion of P1 portion of P1/2 trial in combination with Venclexta for r/r AML
Checkmark Early data from trial in combination with Venetoclax for r/r AML
Dec 2021 - Dec 2021: Early data from trial in combination with Venetoclax for r/r AML
Checkmark From first dose cohort in combination with Venclexta for r/r AML
Dec 2020 - Dec 2020: From first dose cohort in combination with Venclexta for r/r AML
More
Recruiting
1/2
38
US
Lintuzumab-Ac225, Actimab, Venetoclax, Venclexta, Spironolactone, Aldactone
Actinium Pharmaceuticals
Acute Myeloid Leukemia, Relapsed Adult AML
11/23
06/24
NCT03932318: Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Withdrawn
1/2
38
NA
Lintuzumab-Ac225, Actimab, Venetoclax, Venclexta, Azacitidine, Vidaza
Actinium Pharmaceuticals
Acute Myeloid Leukemia, Relapsed Adult AML
12/23
09/24
NCT03441048: Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Checkmark 1-Year and 2-Year overall survival data from a trial for R/R AML at ASH 2022
Nov 2022 - Nov 2022: 1-Year and 2-Year overall survival data from a trial for R/R AML at ASH 2022
Hourglass Jun 2021 - Dec 2021 : Completion of fourth cohort of P1 trial in combination with CLAG-M for r/r AML
Checkmark Data from trial in combination with CLAG-M for r/r AML
Dec 2021 - Dec 2021: Data from trial in combination with CLAG-M for r/r AML
More
Completed
1
26
US
Lintuzumab-Ac-225, HuM195-Ac225, Actimab-A, Cladribine, Leustatin, Mavenclad, Cytarabine, Cytosar-U, Depocyt, cytosine arabinoside (ara-C), Mitoxantrone, Mitozantrone, Novantrone, G-CSF, colony-stimulating factor 3 (CSF 3)
Medical College of Wisconsin
Acute Myeloid Leukemia
05/24
05/24
Bismab-A (lintuzumab-Bi-213) / Actinium
No trials found

Download Options